SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL

3235-0104 OMB Number: Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person [*] Copmann Thomas Lyle	2. Date of Event Requiring Statement (Month/Day/Year) 04/12/2006 3. Issuer Name and Ticker or Trading Symbol Vanda Pharmaceuticals Inc. [VNDA]						
(Last) (First) (Middle) 9605 MEDICAL CENTER DRIVE, SUITE			4. Relationship of Reporting Perso (Check all applicable) Director	on(s) to Issue 10% Owne	(Mon	5. If Amendment, Date of Original Filed (Month/Day/Year)	
300			X Officer (give title below) VP of Regulatory	Other (spee below) Affairs	Appli	cable Line)	/Group Filing (Check
(Street) ROCKVILLE MD 20850							More than One
(City) (State) (Zip)							
Table I - Non-Derivative Securities Beneficially Owned							
1. Title of Security (Instr. 4)			2. Amount of Securities Beneficially Owned (Instr. 4)			Nature of Indirect Beneficial Ownership nstr. 5)	
Common Stock			22,660 ⁽¹⁾	D			
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)							
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securit Underlying Derivative Security		4. Conversion or Exercise Price of	5. Ownership Form: Direct (D)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	Derivative Security		
Nonqualified Stock Option (Right to Buy)	12/29/2006 ⁽²⁾	12/29/2015	Common Stock	12,689(1)	4.73 ⁽³⁾	D	

Explanation of Responses:

1. Reflects a 1-for-3.309755 reverse stock split to occur immediately following the effectiveness of the registration statement covering the issuer's initial public offering.

2. Exercisable with respect to 25% of the shares of 12/29/06. Exercisable with respect to an additional 2.08333% of the aggregate option share total each month thereafter.

3. Reflects the converted exercise price of each option share pursuant to the 1-for-3.309755 reverse stock split to occur immediately following the effectiveness of the registration statement covering the issuer's initial public offering.

/s/ Thomas Copmann

** Signature of Reporting Person

04/12/2006

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 \ast If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.